Pharmosa Biopharm (ROCO:6875) EV-to-EBIT : 367.34 (As of Jun. 06, 2024)

Pharmosa Biopharm EV-to-EBIT Chart

Pharmosa Biopharm Quarterly Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial									-53.27	-53.29	166.34	838.35	382.27

Competitive Comparison of Pharmosa Biopharm's EV-to-EBIT

For the Biotechnology subindustry, Pharmosa Biopharm's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmosa Biopharm's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmosa Biopharm's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pharmosa Biopharm's EV-to-EBIT falls into.

Pharmosa Biopharm EV-to-EBIT Calculation

Pharmosa Biopharm's EV-to-EBIT for today is calculated as:

Pharmosa Biopharm's current Enterprise Value is NT$8,253.5 Mil.
Pharmosa Biopharm's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$22.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmosa Biopharm  (ROCO:6875) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Pharmosa Biopharm's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Pharmosa Biopharm's Enterprise Value for the quarter that ended in Mar. 2024 was NT$8,588.9 Mil.
Pharmosa Biopharm's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$22.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmosa Biopharm EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Pharmosa Biopharm's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmosa Biopharm (ROCO:6875) Business Description